Innate Pharma S.A. (LON:0EVI)

Market Cap	124.84M -17.8%
Revenue (ttm)	7.86M -55.2%
Net Income	-42.90M
EPS	-0.48
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,417
Open	1.618
Previous Close	1.582
Day's Range	1.554 - 1.618
52-Week Range	1.040 - 2.200
Beta	0.81
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 17, 2026

About Innate Pharma

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking ant...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 164
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0EVI

Financial Performance

In 2025, Innate Pharma's revenue was 9.01 million, a decrease of -55.25% compared to the previous year's 20.12 million. Losses were -49.18 million, -0.59% less than in 2024.

Financial numbers in EUR